GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Earnings per Share (Diluted)

Vicapsys Life Sciences (Vicapsys Life Sciences) Earnings per Share (Diluted) : $-0.03 (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Earnings per Share (Diluted)?

Vicapsys Life Sciences's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.03.

Vicapsys Life Sciences's EPS (Basic) for the three months ended in Sep. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.03.

Vicapsys Life Sciences's EPS without NRI for the three months ended in Sep. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.03.

During the past 3 years, the average EPS without NRIGrowth Rate was 42.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 74.40% per year.

During the past 6 years, Vicapsys Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 85.10% per year. The lowest was 42.50% per year. And the median was 82.30% per year.


Vicapsys Life Sciences Earnings per Share (Diluted) Historical Data

The historical data trend for Vicapsys Life Sciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Earnings per Share (Diluted) Chart

Vicapsys Life Sciences Annual Data
Trend Dec08 Dec09 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial -4.80 -0.13 -0.04 -0.01 -0.03

Vicapsys Life Sciences Quarterly Data
Jun10 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 - -0.01

Competitive Comparison of Vicapsys Life Sciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Vicapsys Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicapsys Life Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicapsys Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vicapsys Life Sciences's PE Ratio falls into.



Vicapsys Life Sciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Vicapsys Life Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.985-0)/30.578
=-0.03

Vicapsys Life Sciences's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (Q: Sep. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.24-0)/34.405
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Vicapsys Life Sciences  (OTCPK:VICP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vicapsys Life Sciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
Moore Bobby M Jr 10 percent owner 4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen 10 percent owner 9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski director 1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping 10 percent owner 2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees director C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser director 641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier director 1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon director, 10 percent owner 8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus